Neurosteroids exert diverse modulatory actions on dopamine neurotransmission and signaling. We previously documented that the enzyme 5 alpha-reductase, which catalyzes the main rate-limiting step in neurosteroid synthesis, is required for the behavioral responses of Sprague-Dawley rats to non-selective dopaminergic agonists, such as the D-1-D-2 receptor agonist apomorphine. Specifically, systemic and intra-accumbal administrations of the 5 alpha-reductase inhibitor finasteride countered apomorphine-induced deficits of sensorimotor gating, as measured by the prepulse inhibition (PPI) of the startle reflex; the classes of dopamine receptors involved in these effects, however, remain unknown. Prior rodent studies have revealed that the contributions of dopamine receptors to PPI regulation vary depending on the genetic background; thus, we analyzed the effect of finasteride on the PPI deficits induced by selective dopamine receptor agonists in Long-Evans (a strain exhibiting PPI deficits in response to both D-1 and D-2 receptor agonists) and Sprague Dawley rats (which display PPI reductions following treatment with D-2, and D-3, but not D-1 receptor agonists). In Long Evans rats, finasteride opposed the PPI deficits induced by activation of D-1, but not D-2 receptors; conversely, in Sprague-Dawley rats, finasteride prevented the reductions in %PPI and accumbal dopamine extracellular levels caused by selective stimulation of D-3, but not D-2 receptors; however, the effects on %PPI were not confirmed by analyses on absolute PPI values. Our findings suggest that 5 alpha-reductase modulates the effects of D-1, but not D-2 receptor agonists on sensorimotor gating. These data may help elucidate the role of neurosteroids in neuropsychiatric disorders featuring PPI deficits, including schizophrenia and Tourette syndrome

The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating

FRAU, ROBERTO;BINI, VALENTINA;PILLOLLA, GIULIANO;PES, ROMINA;SABA, PIERLUIGI;FANNI, SILVIA;DEVOTO, PAOLA;
2016

Abstract

Neurosteroids exert diverse modulatory actions on dopamine neurotransmission and signaling. We previously documented that the enzyme 5 alpha-reductase, which catalyzes the main rate-limiting step in neurosteroid synthesis, is required for the behavioral responses of Sprague-Dawley rats to non-selective dopaminergic agonists, such as the D-1-D-2 receptor agonist apomorphine. Specifically, systemic and intra-accumbal administrations of the 5 alpha-reductase inhibitor finasteride countered apomorphine-induced deficits of sensorimotor gating, as measured by the prepulse inhibition (PPI) of the startle reflex; the classes of dopamine receptors involved in these effects, however, remain unknown. Prior rodent studies have revealed that the contributions of dopamine receptors to PPI regulation vary depending on the genetic background; thus, we analyzed the effect of finasteride on the PPI deficits induced by selective dopamine receptor agonists in Long-Evans (a strain exhibiting PPI deficits in response to both D-1 and D-2 receptor agonists) and Sprague Dawley rats (which display PPI reductions following treatment with D-2, and D-3, but not D-1 receptor agonists). In Long Evans rats, finasteride opposed the PPI deficits induced by activation of D-1, but not D-2 receptors; conversely, in Sprague-Dawley rats, finasteride prevented the reductions in %PPI and accumbal dopamine extracellular levels caused by selective stimulation of D-3, but not D-2 receptors; however, the effects on %PPI were not confirmed by analyses on absolute PPI values. Our findings suggest that 5 alpha-reductase modulates the effects of D-1, but not D-2 receptor agonists on sensorimotor gating. These data may help elucidate the role of neurosteroids in neuropsychiatric disorders featuring PPI deficits, including schizophrenia and Tourette syndrome
5α-Reductase, Dopamine, Finasteride, Neurosteroids, Prepulse inhibition of the startle, Endocrinology, Endocrinology diabetes and metabolism, Psychiatry and mental health, Biological psychiatry, Endocrine and autonomic systems
File in questo prodotto:
File Dimensione Formato  
PNEC2015_Frau et al.pdf

Solo gestori archivio

Tipologia: versione editoriale
Dimensione 1.52 MB
Formato Adobe PDF
1.52 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/135747
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 30
social impact